CONTACT US
- PRODUCT ENQUIRIES
- MEDIA ENQUIRIES
- ADVERSE EFFECTS
-
Adverse events in the UK should be reported through the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme
In the Republic of Ireland through the Health Products Regulatory Authority (HPRA)
Adverse events and Product quality complaints should also be reported directly to Perrigo UK and Ireland:
Omega Pharma Ltd.
One Embassy Gardens,
8 Viaduct Gardens,
London, SW11 7BW
United Kingdom
*IRI hay fever remedies unit sales 52 w/e 23rd Feb 2019. For verification please email verify@perrigo.com
(1) Del Cuvillo A, Mullol J, Bartra J, Dvila I, Juregui I, Montoro J, Sastre J, Valeron AL. Comparative pharmacology of the H1 antihistamines. J Invest Alergol Clin Immunol 2006;16(S1):3-12.
(2) Schran HF, Petryk L, Chang CT, O’Connor R, Gelbert MB. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol 1996;36:911-922.
(3) Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36(5):329-52.
(4) Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma Immunol 2000;84(4):451-459.
Beconase Hay fever and Beconase Hay fever Relief for Adults 0.05% Nasal Spray contains beclometasone dipropionate. For the treatment of hay fever in adults aged 18 and over. Becodefence, Becodefence Kids and Becodefence Plus are medical devices. Always read the leaflet.